AVENIO ctDNA Expanded Kit V2
For Research Use Only. Not for use in diagnostic procedures.
Overview
The AVENIO ctDNA Expanded Kit V2 is a next-generation sequencing (NGS) liquid biopsy assay with a 77 gene panel containing genes in U.S. National Comprehensive Cancer Network (NCCN) Guidelines1 and emerging cancer biomarkers. It is a pan-cancer assay that’s specially optimized for lung cancer and colorectal cancer (CRC) research.
Features and Benefits
- Contains genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines1 and emerging cancer biomarkers
- All four mutation classes (SNVs, indels, fusions and CNVs) in a single assay
- Exceptional analytical performance supported by integrated digital error suppression (iDES) strategies combining molecular barcodes with in silico error suppression techniques2,3
- Includes reagents, bioinformatics and software
- Streamlined, end-to-end workflow from extraction to analysis and reporting in five days
A portfolio of NGS liquid biopsy assays
The AVENIO ctDNA Expanded Kit V2 is one of three assays in the AVENIO ctDNA research assay portfolio. Learn more about the 17-gene AVENIO ctDNA Targeted Kit V2 for guideline-driven tumor profiling or the 197-gene AVENIO ctDNA Surveillance Kit V2 for longitudinal tumor burden monitoring.
References
- National Comprehensive Cancer Network. Accessed August 2, 2023.
- Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine. 2014;20(5):548–554 doi:10.1038/nm.3519
- Data on file with Roche.